SciSparc receives FDA approval for trial for Tourette syndrome therapy [Yahoo! Finance]
SciSparc Ltd. (SPRC)
Company Research
Source: Yahoo! Finance
Trial subjects will be randomised into a 1:1 ratio to receive either SCI-110 or a matched placebo. The trial's main efficacy measure is evaluating the variation change in tic severity using the Yale Global Tic Severity Scale at weeks 12 and 26 of the double-blind phase compared to the baseline. Its primary safety goal is to analyse the absolute and relative frequencies of serious adverse events among all trial subjects, as well as for the SCI-110 and placebo arms separately. SciSparc CEO Oz Adler said: “As the currently used medications are managing only a small number of disease symptoms with limited efficacy and questionable safety, we believe there is a clear unmet medical need for the management of Tourette syndrome. “In light of the results from our Phase IIa clinical trial conducted at Yale University that showed an average tic reduction of 21% across the entire sample with almost 40% of the patients experiencing greater than 25% in tic reduction, we believe that our in
Show less
Read more
Impact Snapshot
Event Time:
SPRC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRC alerts
High impacting SciSparc Ltd. news events
Weekly update
A roundup of the hottest topics
SPRC
News
- SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment [Yahoo! Finance]Yahoo! Finance
- SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentGlobeNewswire
- SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX [Yahoo! Finance]Yahoo! Finance
- SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareXGlobeNewswire
- SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate Sep. 23, 2024 2:18 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]Seeking Alpha
SPRC
Sec Filings
- 11/4/24 - Form 6-K
- 10/23/24 - Form 6-K
- 10/22/24 - Form 6-K
- SPRC's page on the SEC website